ArticleACS omega2026
A Novel Voltammetric Point-of-Care Device for Rapid and Accurate Nucleic Acid and Viral Pathogen Detection.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With zoonotic outbreaks on the rise, rapid and accurate infectious disease diagnostics are critical for both human and animal health. Traditional lateral flow assays lack sensitivity and specificity, while isothermal amplification methods like LAMP, though rapid, can be hindered by optical detection issues. We present an electrochemical nucleic acid amplification test (NAAT) that combines isothermal amplification with real-time voltammetric detection. This novel method relies on monitoring of amplification-associated proton release through redox probing of a pH-sensing compound. The method shows high concordance with RT-qPCR under the tested conditions and demonstrates a limit of detection (LOD) of 50 copies/reaction for IAV. In RNA purified from clinical samples, 231/234 (98.7%) are concordant with RT-qPCR for SARS-CoV-2, IAV, IBV, or RSV A. In a proof-of-concept extraction-free workflow, 14/14 equine nasal swab samples are correctly classified for EHV-5 relative to qPCR. Together, these data support the feasibility of real-time voltammetric LAMP across several sample types, while broader point-of-care validation across additional matrices and prospective cohorts remains to be established.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.